Interview with Pavel Chistyakov, General Manager, Pierre Fabre Russia
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
Address: 119435 г.Москва, Саввинская набережная, д. 11,Russia
Tel: +7 (495) 789 9533
Web: http://www.pierre-fabre-Russia.ru/
Today, almost half a century since its founding, the Pierre Fabre Group is the second largest private pharmaceutical company in France and has market presence in over 140 countries around the world. Business within the company’s Russian affiliate is beginning to evolve rapidly. In 1993, the first drug produced by Pierre Fabre appeared on the Russian market. In 1999, the Group began selling skin care products through its exclusive distributor. In 2008, the decision was made to merge all areas in Russia, and in 2009, the company opened a 100% Russian subsidiary. In May 2009, the first skin care products were delivered to the affiliate from France, and in 2010, the first dental products were delivered.
In Russia, the main activity of LLC Pierre Fabre is the promotion of skin cosmetics, which are divided in two areas: dermatology and aesthetic skin care.
Pierre Fabre’s skin care products are sold exclusively in pharmacies.
Dermo-cosmetics and pharmaceutical products
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
You founded Euroservice, and have managed this business since its inception in 1996. What are the key drivers that have facilitated the growth of this company from a staff of…
In spring of 2010, Protek became the first Russian wholesaler to enter the public stock market, raising $400Mn in the biggest Russian IPO since 2007. You offered the IPO directly…
PAREXEL prides itself on improving the time schedule of a product launch. What is the significance of time-to-market in the healthcare industry, and how can PAREXEL expedite the process better…
Since our last report on Russia in 2007, there has been much emphasis placed on developing local industry, and reducing the nation’s reliance on imported pharmaceutical products. How do you…
You worked for ten years at Schering-Plough—one of the largest pharmaceutical companies in the world. In February of last year, you joined Merz Pharma, a much smaller player. Some may…
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
Russia and India have recently held a number of discussions regarding increased cooperation within the pharmaceutical sector. For example, the two nation’s health ministers have discussed decreasing administrative barriers to…
Biofund is an independent spin-off of the broader Russian Venture Capital organization. What is the working relationship and synergy between these agencies, and what are the market conditions that have…
Petrovax has always been an innovative company, making it quite unique in Russia where the domestic industry is predominantly comprised of generics manufacturers. How would you describe the positioning of…
After a long history in Philips, this is your first tenure as a regional CEO. Having been at this position for less than a year, what are your impressions of…
You were a Russian manager from 1996-2004, departed to Germany for some time, and recently made your way back to Russia in 2010. How has Russian healthcare and industry changed,…
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
See our Cookie Privacy Policy Here